Study designs of evaluations included in the review
Clinical trials were included.
Specific interventions included in the review
Zolpidem (5 to 20 mg/day) and triazolam (0.125 to 0.5 mg/day); both are short-acting sedative-hypnotics.
Participants included in the review
People with insomnia, including populations from general practice, psychiatric in--patients and outpatients, and the elderly.
Outcomes assessed in the review
Several outcomes were assessed: sleep-related outcomes such as sleep onset latency, duration and quality of sleep, number of nocturnal wakenings and nocturnal awake time; daytime residual effects; memory impairment; and other adverse effects such as dizziness, headaches and nausea.
How were decisions on the relevance of primary studies made?
The authors do not state how the papers were selected for the review, or how many of the authors performed the selection.